# Professor 6: VEP/PLM expert (strictness=highest)

## Scores
A: 8.0
B: 7.5
C: 7.0
D: 7.0
E: 8.0
F: 7.5
G: 6.5
H: 7.0
I: 9.0
J: 7.5
total: 75.0/100

## Rationale (≤3 sentences each item)
A: The problem is now sharply bounded as region-level, single-position hotspot prioritization for retrospective wet-lab triage, not prospective VEP or universal escape prediction. The manuscript clearly distinguishes standardized benchmarking, pathogen-dependent information utility, and external escape enrichment as separate problems. The remaining weakness is that "hotspot" still mixes adaptive, escape, HVR, and functional-region semantics, so the problem definition is operationally clear but biologically heterogeneous.

B: Related work is broad and mostly current, with appropriate separation from ProteinGym, EVEREST, ViroGym, EVEscape, surveillance systems, phylogenetic selection tools, and cancer hotspot methods. From a VEP/PLM perspective, the coverage is less strong because Tranception is not actually run, EVEscape is a proxy composite, ESM-3 is only license-excluded, and no direct task-aligned binarization of VEP outputs is attempted. The task-orthogonality argument is valid, but it also prevents the dissertation from proving competitive standing against modern viral VEP benchmarks.

C: The methodology is serious: 20 scoring formulas, 39 detector variants, Layer A/B/C labels, MCC-centered evaluation, cluster bootstrap, ANCOVA, Bayesian and null-calibration checks, and explicit nested-LOPO separation for label-aware fusion. Major deductions remain for single-team Layer A curation, heterogeneous label provenance, PLM proxy collinearity, monomer-only structural features for oligomeric proteins, MAFFT-auto confounding, and reliance on retrospective labels. The ANOVA interaction is defensible within the panel, but it is not a causal decomposition of pathogen biology versus data quality versus curation style.

D: The 8,580-cell benchmark is large for region-level viral hotspot detection and spans 11 RNA-virus surface glycoproteins across multiple families. It is still modest by VEP benchmark standards: only 11 headline pathogens, DMS Layer C for 6/11, escape validation for 3/11, and no broad multi-protein or non-surface panel. The dissertation correctly admits that n=11 is below the 20-30 pathogen regime needed for stable adaptive inference, which caps the scale score.

E: Interpretation is substantially improved because LOPO 0/11, Friedman p=0.990, HBFWS p=0.78, Cycle 7B failures, Wave 4, and Wave 5 are framed as bounded negative evidence rather than hidden successes. The HIV-1 anchor is correctly prioritized over H3N2 self-consistency and SARS-CoV-2 exploratory evidence. Some practical-language passages still read stronger than the null-calibrated and 0/12-callable results warrant, especially around cold-start recommendations.

F: The strongest novelty is the task-specific benchmark: quantifying scoring-by-pathogen interaction for region-level viral hotspot detection is a plausible original contribution. The work is less novel as a VEP/PLM contribution because it reuses ESM-2-derived proxies, does not introduce a new PLM method, and explicitly defers head-to-head task adaptation against EVEREST/ViroGym/ProteinGym-style predictors. Novelty is therefore good as benchmark infrastructure and evidence synthesis, not as a new predictive model.

G: Practical value exists as retrospective search-space reduction, especially HIV-1 7.19x escape enrichment with 82% Layer-A-disjoint support and novel-only Bonferroni survival. However, prospective value is weak: sliding-window grand mean AUROC is 0.539, adaptive selectors fail, Wave 5 reverses sign under Layer A', and the predeclared callability rule abstains on 0/12 folds. The usable product today is a triage heuristic with abstention, not a deployable surveillance or vaccine-design engine.

H: The manuscript is technically explicit and unusually transparent, but it is dense, ledger-heavy, and sometimes forces the reader through many cross-references to understand which panel, protocol, or EqualWeight variant is active. The distinction among 11-pathogen Stage 2, 12-pathogen Stage 3, Wave 4, Wave 5, production EqualWeight, and nested-LOPO EqualWeight is handled, but it remains cognitively expensive. Clarity is acceptable for examiners, less so for ordinary method users.

I: Limitations awareness is the dissertation's strongest dimension. It directly acknowledges label heterogeneity, PLM leakage/proxy redundancy, winner's curse, small-cluster inference, prospective validation failure, dual-use risk, structural-model limitations, MAFFT-auto artifacts, and lack of independent reproduction. The only reason this is not a 10 is that several mitigations are disclosure and sensitivity framing rather than fully resolved experimental controls.

J: Overall maturity is good: the work has a coherent artifact, reproducibility/provenance claims, multiple robustness frames, and a mature habit of downgrading claims when audits fail. The residual immaturity is not presentation alone but evidential: independent recuration, external rerun, task-aligned VEP comparison, and expanded pathogen panels remain future work. I would consider it defensible as a bounded benchmark dissertation after revision polish, not as a mature deployable predictor.

## Critical concerns (if any item < 6)
None.

## Strongest single deduction
G, because the manuscript's strongest practical claim remains retrospective HIV-1-centered triage while prospective transfer, adaptive selection, and formal callability all fail; fix by adding an externally curated 20-30+ pathogen time-forward panel with predeclared callability and task-aligned VEP baselines.

RESULT_PROF_V7_06: total=75.0/100 min_item=6.5(G) max_item=9.0(I)
